(Q59382383)

1 July 2019

title

Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients (English)

1 reference

1 July 2019

main subject

phase I clinical trial

1 reference

4

1 reference

1 July 2019

Benjamin F Johnson

9

1 reference

1 July 2019

author name string

Edwin P Hui

1

1 reference

1 July 2019

Graham S Taylor

2

1 reference

1 July 2019

Hui Jia

3

1 reference

1 July 2019

Stephen L Chan

5

1 reference

1 July 2019

Rosalie Ho

6

1 reference

1 July 2019

Wai-Lap Wong

7

1 reference

1 July 2019

Steven Wilson

8

1 reference

1 July 2019

Ceri Edwards

10

1 reference

1 July 2019

Deborah D Stocken

11

1 reference

1 July 2019

Alan B Rickinson

12

1 reference

1 July 2019

Neil M Steven

13

1 reference

1 July 2019

Anthony T C Chan

14

1 reference

1 July 2019

language of work or name

English

0 references

publication date

24 January 2013

1 reference

1 July 2019

published in

Cancer Research

1 reference

1 July 2019

volume

73

1 reference

1 July 2019

issue

6

1 reference

1 July 2019

page(s)

1676-1688

1 reference

1 July 2019

Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma

cites work

1 reference

12 December 2020

CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells

1 reference

12 December 2020

Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma

1 reference

12 December 2020

Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma

1 reference

12 December 2020

Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.

1 reference

12 December 2020

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

12 December 2020

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

12 December 2020

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

12 December 2020

Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts

1 reference

12 December 2020

Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma

1 reference

12 December 2020

Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes

1 reference

12 December 2020

CD4 T cell-dependent CD8 T cell maturation

1 reference

12 December 2020

CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1

1 reference

12 December 2020

Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

1 reference

12 December 2020

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

1 reference

12 December 2020

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

12 December 2020

Epstein-Barr virus: 40 years on

1 reference

12 December 2020

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

1 reference

12 December 2020

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

1 reference

12 December 2020

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

1 reference

12 December 2020

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

1 reference

12 December 2020

The global health burden of infection-associated cancers in the year 2002

1 reference

12 December 2020

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

1 reference

12 December 2020

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

1 reference

12 December 2020

CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.

1 reference

12 December 2020

Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays

1 reference

12 December 2020

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

1 reference

12 December 2020

Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma

1 reference

12 December 2020

Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients

1 reference

12 December 2020

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

1 reference

12 December 2020

Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy

1 reference

12 December 2020

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

1 reference

12 December 2020

CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.

1 reference

12 December 2020

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

1 reference

12 December 2020

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

1 reference

12 December 2020

Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia

1 reference

12 December 2020

Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma

1 reference

12 December 2020

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

1 reference

12 December 2020

Nasopharyngeal carcinoma: the next challenges

1 reference

12 December 2020

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

1 reference

12 December 2020

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

1 reference

12 December 2020

Treatment for metastatic nasopharyngeal carcinoma

1 reference

12 December 2020

Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy

1 reference

12 December 2020

Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells

1 reference

12 December 2020

10.1158/0008-5472.CAN-12-2448

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6485495

1 reference

1 July 2019

PubMed publication ID

23348421

1 reference

1 July 2019